Literature DB >> 22941036

Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.

Lixin Zhang1, Anda Vlad, Christine Milcarek, Olivera J Finn.   

Abstract

MUC1 is a transmembrane mucin with important functions in normal and transformed cells, carried out by the extracellular domain or the cytoplasmic tail. A characteristic feature of the MUC1 extracellular domain is the variable number of tandem repeats (VNTR) region. Alternative splicing may regulate MUC1 expression and possibly function. We developed an RT-PCR method for efficient isolation of MUC1 mRNA isoforms that allowed us to evaluate the extent of alternative splicing of MUC1 and elucidate some of the rules that govern this process. We cloned and analyzed 21, 24, and 36 isoforms from human tumor cell lines HeLa, MCF7, and Jurkat, respectively, and 16 from normal activated human T cells. Among the 78 MUC1 isoforms we isolated, 76 are new and different cells showed varied MUC1 expression patterns. The VNTR region of exon 2 was recognized as an intron with a fixed 5' splice site but variable 3' splice sites. We also report that the 3506 A/G SNP in exon 2 can regulate 3' splice sites selection in intron 1 and produce different MUC1 short isoform proteins. Furthermore, the SNP A to G mutation was also observed in vivo, during de novo tumor formation in MUC1(+/-)Kras(G12D/+)Pten(loxP/loxP) mice. No specific functions have been associated with previously reported short isoforms. We now report that one new G SNP-associated isoform MUC1/Y-LSP, but not the A SNP-associated isoform MUC1/Y, inhibits tumor growth in immunocompetent but not immunocompromised mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941036      PMCID: PMC3538090          DOI: 10.1007/s00262-012-1325-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  63 in total

1.  A genomic view of alternative splicing.

Authors:  Barmak Modrek; Christopher Lee
Journal:  Nat Genet       Date:  2002-01       Impact factor: 38.330

Review 2.  Alternative splicing: combinatorial output from the genome.

Authors:  Gavin C Roberts; Christopher W J Smith
Journal:  Curr Opin Chem Biol       Date:  2002-06       Impact factor: 8.822

Review 3.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

Review 4.  Pre-mRNA splicing and human disease.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

5.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

Review 6.  Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome.

Authors:  Stefan Stamm
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

Review 7.  Alternative splicing: new insights from global analyses.

Authors:  Benjamin J Blencowe
Journal:  Cell       Date:  2006-07-14       Impact factor: 41.582

Review 8.  Roles of mucin-type O-glycans in cell adhesion.

Authors:  Minoru Fukuda
Journal:  Biochim Biophys Acta       Date:  2002-12-19

9.  Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Paolo Malinconico; Andrea Stoler; Leila Andreocci; Dino Parente; Annamaria Coscarella; Nicola Maggiano; Alessandro Perillo; Luca Pierelli; Giovanni Scambia
Journal:  Exp Cell Res       Date:  2002-10-15       Impact factor: 3.905

10.  Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling.

Authors:  Jian Ren; Yongqing Li; Donald Kufe
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

View more
  15 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  A balanced level of profilin-1 promotes stemness and tumor-initiating potential of breast cancer cells.

Authors:  Chang Jiang; Zhijie Ding; Marion Joy; Souvik Chakraborty; Su Hyeong Kim; Ralph Bottcher; John Condeelis; Shivendra Singh; Partha Roy
Journal:  Cell Cycle       Date:  2017       Impact factor: 4.534

3.  Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma.

Authors:  Yoshiaki Kamikawa; Yuji Kanmura; Tomofumi Hamada; Norishige Yamada; Muzafar A Macha; Surinder K Batra; Michiyo Higashi; Suguru Yonezawa; Kazumasa Sugihara
Journal:  Int J Clin Oncol       Date:  2014-06-10       Impact factor: 3.402

4.  Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer.

Authors:  Kolsoum Rezaie Kahkhaie; Omeed Moaven; Mohammad Reza Abbaszadegan; Mehdi Montazer; Mehran Gholamin
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

Review 5.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

6.  Alternative splicing regulation of telomerase: a new paradigm?

Authors:  Mandy S Wong; Woodring E Wright; Jerry W Shay
Journal:  Trends Genet       Date:  2014-08-26       Impact factor: 11.639

Review 7.  MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Authors:  Sritama Nath; Pinku Mukherjee
Journal:  Trends Mol Med       Date:  2014-03-22       Impact factor: 11.951

8.  Type I Interferon Dependent hsa-miR-145-5p Downregulation Modulates MUC1 and TLR4 Overexpression in Salivary Glands From Sjögren's Syndrome Patients.

Authors:  Daniela Jara; Patricia Carvajal; Isabel Castro; María-José Barrera; Sergio Aguilera; Sergio González; Claudio Molina; Marcela Hermoso; María-Julieta González
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  Aberrant MUC1-TRIM46-KRTCAP2 Chimeric RNAs in High-Grade Serous Ovarian Carcinoma.

Authors:  Kalpana Kannan; Gona Karimi Kordestani; Anika Galagoda; Cristian Coarfa; Laising Yen
Journal:  Cancers (Basel)       Date:  2015-10-19       Impact factor: 6.639

Review 10.  Mucin in cancer: a stealth cloak for cancer cells.

Authors:  Dong-Han Wi; Jong-Ho Cha; Youn-Sang Jung
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.